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ABSTRACT
Topoisomerase II plays a crucial role during chromo-
some condensation and segregation in mitosis and
meiosis and is a highly attractive target for chemo-
therapeutic agents. We have identified previously
topoisomerase II and heat shock protein 90 (Hsp90)
aspartofacomplex.Inthispaperwedemonstratethat
drug combinations targeting these two enzymes
causeasynergisticincreaseinapoptosis.Theobject-
ive ofour study wasto identify themodeof cellkilling
and the mechanism behind the increase in topoi-
somerase II mediated DNA damage. Importantly we
demonstrate that Hsp90 inhibition results in an
increased topoiosmerase II activity but not degrada-
tion of topoisomerase II and it is this, in the presence
of a topoisomerase II poison that causes the increase
in cell death. Our results suggest a novel mechanism
of action where the inhibition of Hsp90 disrupts the
Hsp90–topoisomerase II interaction leading to an
increaseinandactivationofunboundtopoisomerase
II,which,inthepresenceofatopoisomeraseIIpoison
leads to the formation of an increased number of
cleavable complexes ultimately resulting in rise in
DNA damage and a subsequent increase cell death.
INTRODUCTION
Topoisomerase II is required for the viability of all eukaryotic
cells and plays important roles in DNA replication, recomb-
ination, transcription, chromosome segregation and the
maintenance of the nuclear scaffold. In human and other mam-
malian cells, there are at least two forms (a and b) of the
topoisomerase II enzyme (1,2). Topoisomerase II catalyses
a transient double-stranded break in the DNA helix, allowing
the passing of a second double strand of DNA through the
break, which is then religated. Topoisomerase poisons acts by
prolonging the lifetime of these open intermediate ‘cleavable
complexes’ forming obstructions that eventually lead to DNA
damage (3). DNA damage is normally sensed by ATM or ATR
complexes upon double-strand breakage, which signals a cas-
cade of events leading to Chk1 phosphorylation that in turn
phosphorylates Cdc25A causing its inactivation by nuclear
exclusion and degradation. The DNA damage signal via
Chk1 also regulates Cdk1 (Cdc2)/Cyclin B, Wee1 and
Cdc25A proteins that are crucial for the G2/M transition,
by changing their expression, phosphorylation and cellular
localization (4). Our research has previously identiﬁed topoi-
somerase II and heat shock protein 90 (Hsp90) as part of
a complex (5).
Hsp90 is an essential and ubiquitous molecular chaperone
that plays an important physiological role in the folding,
activation and assembly of a broad range of client proteins
(6). Hsp90 has become a target for cancer therapeutics as
Hsp90 is up-regulated in numerous tumour cells (7), also
the Hsp90 in these cells is primarily found in multi-protein
complexes (8). It is proposed that Hsp90 ‘hides and protects’
mutant and defective proteins during the progression of a can-
cer. In particular Hsp90 interacts with the numerous mutated
proteins found within such tumour cells and acts to prevent
their detection by the G1 and G2/M cell cycle checkpoint
apparatus (9). Inhibitors of Hsp90 [17-allylamino-17-
demethoxygeldanamycin (17-AAG) and its parent compound
geldanamycin] bind to the ATP-binding site of Hsp90 and act
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destabilizing the Hsp90–client protein interaction causing
the degradation of a number of client proteins (10–13).
The effect of topoisomerase II poisons in conjunction with
Hsp90 inhibitors has received little attention. Previous studies
have focused on the use of Hsp90 inhibitors in combination
with doxorubicin, which has a number of modes of action, one
of which is as a topoisomerase II poison (14,15). Evidence for
any synergistic effect is conﬂicting with synergy being
observed for breast cancer derived cell lines (15) but not
cells expressing Bcr-Abl (14).
We have shown previously that inhibition of Hsp90
enhances the cell killing properties of topoisomerase II pois-
ons in a p53 independent manner; however, the mode of cell
death and its mechanism were not characterized (5). In this
paper we demonstrate that inhibition of Hsp90 (geldanamycin)
sensitizes cells to a topoisomerase II poison (etoposide), that
this effect issynergistic over a range of concentrations and that
cell death is via apoptosis. In this paper we also hypothesize
that the apoptosis induced by the combination of a topoi-
somerase II poison and an Hsp90 inhibitor occurs via a previ-
ously unidentiﬁed, topoisomerase II dependant mechanism.
The synergistic killing effect appears to be mediated via an
activation of topoisomerase II, which because of the presence
of the topoisomerase II poison leads to an increase in DNA
damage, for which we propose a model. Understanding the
processes behind the drug combination effect is important
because it will have profound effects on the way that topoi-




Theisogenichumancolon cancer celllines, HCT116 wildtype
(WT) and p53
 / , were a kind gift from Prof. B. Vogelstein,
TheJohn Hopkins Medical Institutions(Baltimore,MD).Cells
were maintained in McCoys 5A medium (Sigma-Aldrich
Company Ltd, Poole, Dorset, UK) supplemented with 10%
foetal calf serum (Invitrogen Ltd, Paisley, Scotland, UK) at
37 C in a 5% CO2 enriched humidiﬁed environment.
Drugs
Vepesid  (etoposide) was obtained from Bristol-Myers
Pharmaceuticals (Hounslow, UK) and Novantrone  (mitox-
antrone) from Cyanamid (Gosport, Hampshire, UK).
Geldanamycin was a kind gift from Dr R. J. Schultz, Drug
Synthesis and Chemistry Branch, Developmental Therapeut-
ics Program, National Cancer Institute (Rockville, MD).
Geldanamycin was also obtained from Tocris Cookson
Ltd (Avonmouth, UK) and radicicol was obtained from
Sigma-Aldrich Company Ltd.
Antibodies
Rabbit anti-topoisomerase IIa, mouse anti-(pan)actin, b-actin,
antibodies were purchased from Lab Vision (UK) Ltd
(Newmarket, Suffolk, UK), Chk1 antibody from Abcam Ltd
(Cambridge, UK) and the rabbit anti-topoisomerase IIb
(IHIC2) antibody was a kind gift from Prof. I. Hickson
(Weatherall Institute of Molecular Medicine, Oxford, UK).
Immunoblotting
Whole cell extracts were separated by 7.5, 10 or 15%
SDS–PAGE under reducing conditions and blotted onto
Protran  nitrocellulose membrane (Schleicher and Schuell
UK Ltd, London, UK). Blots were probed with appropriate
primary antibodies and the secondary antibodies conjugated
with horseradish peroxidase(DAKOCytomationLtdEly,UK)
detection was by Supersignal  West Dura Extended Substrate
(Perbio Science UK Ltd, Tattenhall, UK) and imaged using
a Fluor-S  bioimager (Bio-Rad Laboratories Ltd, Hemel
Hempstead, UK).
Growth inhibition assay
For growth inhibition studies we used the sulforhodamine B
(SRB) assay as described previously (16). In brief, cells were
seeded into 96-well microtiter plates allowed to adhere over-
night and then drugs were added in six replicate wells for
a period of up to 7 days. At ﬁxed time points cells were
ﬁxed with 3:1 methanol:acetic acid and stained with 0.4%
(w/v) SRB.
Detection of apoptosis by time laps florescence
microscopy
HCT116 cells were seeded at a density of 1 · 10
5 cells in
35 mm glass bottom microwell dishes (MatTek, Ashland,
MA) and left to adhere for 96 h. The MatTek media volume
was adjusted to 2 ml and cells were placed on the CO2
controlled incubated microscope stage for  2 h to equilibrate.
Cells were treated with 2 mM etoposide (VP16), 500 nM
geldanamycin (GA) or the combination of the two in the
presence of 15 mg/ml propidium iodide (Sigma-Aldrich Com-
pany Ltd) and 40 ng/ml annexinV-FITC (BioSource Interna-
tional, Camarillo, CA). Cells were imaged in a humidiﬁed
CO2 incubator (at 37 C, 5% CO2) every 15 min using
a Zeiss Axiovert 200 with a 20· FLUAR objective (Carl
Zeiss Ltd, Welwyn Garden City, Hertfordshire, UK). Excita-
tion of FITC was performed using an argon ion laser at
488 nm. Emitted light was reﬂected through a 505–550 nm
bandpass ﬁlter from a 540 nm dichronic mirror. Propidium
iodide was excited using a green helium neon laser at 543 nm
and detected through a 570 nm long-pass ﬁlter. Data capture
and analysis was performed using LSM510 version 3.2 soft-
ware (Carl Zeiss Ltd). Four ﬁelds from within an individual
treatment were studies and individual cells scored for their
initial staining with annexinV-FITC and/or PI, a minimum of
350 cells per treatment were followed (only the initial staining
event is used to produce a score for a particular cell). Data are
represented as normalized to time zero.
Alkaline single cell gel electrophoresis ‘Comet’ assay
Treated cells were harvested, 1 ml of 1% low melting point
agarose added, transferred to a polysine microscope slide
(BDH, Poole, UK) coated with 1% agarose on ice and allowed
to set. The slides were incubated in the dark in lysis buffer
(100 mM Tris, pH 10.5, 2.5 M NaCl, 100 mM EDTA, 1% v/v
dimethyl sulfoxide and 1% v/v Triton X-100) on ice for 1 h
and washed four times for 15 min with dH2O. DNA was
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1 mM EDTA, pH 12 for 1 h in the dark at 4 C. The slides were
then subjected to electrophoresis at 20 V for 20 min, stained
with 2.5 mg/ml propidium iodide for 1 h and destained with
dH2O for 1 h. Images were captured using a Leica AS LMD
microscope (Leica Microsystems, Milton Keynes, UK) and
comet tail lengths were measured using Leica LMD version
3.1.0.2 software. The data shown in Figure 5 represent at least
three independent drug treatments per time point.
Small-scale preparation of topoisomerase II extracts
Topoisomerase II was extracted from cells according to the
manufacturer’s instructions, Topoisomerase II assay kit
(Topogen Inc., Columbus, OH), with minor modiﬁcations:
NP40 was added to the nuclear lysis buffer, to a ﬁnal concen-
tration of 1%, and an equal volume of 0.5 M NaCl was added
to the resuspended nuclei.
Topoisomerase II DNA decatenation assay
Nuclear extracts were assayed for topoisomerase II activity
using a Topoisomerase II assay kit (Topogen Inc.). The
nuclear extracts were incubated with geldanamycin (GA) or
radicicol (RD) on ice for 15 min, then 0.25–2 ml of these
reactions were incubated with 0.125 mg kinetoplast DNA
(kDNA) in the presence of topoisomerase II assay buffer
(50 mM Tris–HCl, pH 8.0, 120 mM KCl, 10 mM MgCl2,
0.5 mM ATP, 0.5 mM DTT and 30 mg/ml BSA) at 37 C
for 30 min. Reactions were stopped by the addition of 1/5
vol of 5· AGE loading buffer and subjected to agarose gel
electrophoresis and DNA visualized using a FX  molecular
Imager (Bio-Rad Laboratories Ltd).
In vivo complex of enzyme (ICE) assay
The ICE assay was performed as described previously (17).
Brieﬂy, cells were seeded at 1 · 10
6 cells per 150 mm dishes
(ﬁve dishes for each treatment) and allowed to adhere
overnight. The cells were then exposed to the drugs for 1 h,
collected and lysed with 1 ml 1% sarkosyl in TE buffer
(10 mM Tris–HCl, pH 8.0, 1 mM EDTA). The cell lysates
were then placed into polyallomer tubes containing 3 ml
caesium chloride step gradients of 1.82, 1.72, 1.50 and
1.37 g/ml. Samples were then subjected to centrifugation at
20 C in a Beckman SW41 rotor at 30 000 r.p.m. for 24 h.
Approximately 500 ml of each fraction was collected from the
bottom of the tube. A 100 ml aliquot of each fraction was
diluted with 100 ml of 25 mM sodium-phosphate buffer, pH
6.5,andapplied ontoapplied ontopre-soaked(25mMsodium-
phosphate buffer, pH 6.5, for 15 min) Protran  nitrocellulose
membranes using a slot blot vacuum manifold. Membranes
were washed with sodium-phosphate buffer and immuno-
blotted with anti-human topoisomerase IIa antibodies. The
DNA content of each fraction was visualized by agarose
gel electrophoresis.
RESULTS
The combination of a topoisomerase II poison and an
Hsp90 inhibitor cause synergistic apoptosis cell death
In our previous studies we demonstrated that topoisomerase II
and Hsp90 were part of a complex and that Hsp90 inhibition
enhances the cell killing properties of topoisomerase II
poisons in a p53 independent manner. We now want to
showthatthissynergyoccurredoverarangeofdrugratios,that
the mode of cell death is apoptosis and that the combination
affects the timing of the initiation of apoptosis.
We tested the sensitivity of cells, in which the interaction
between Hsp90 and topoisomerase II has been disrupted
by geldanamycin. Cells were treated with a broad range of
etoposide (VP16) concentrations, a topoisomerase II
poison and geldanamycin alone in order to determine the
Figure 1. Growth inhibition assays for HCT116 WT cells. HCT116 WT cells were seeded at a density of 3 · 10
3 per well in 96-well flat-bottomed plates and were
treatedwithetopside(VP16),geldanamycin(GA)orcombinationsofbothfor7days.Atafixedtimepoint,cellswerefixed,stainedwithSRBandreadatA570nm.
(A)SingleVP16doseresponsecurve.Pointsrepresenttheaverageofsixreplicatesasapercentagegrowthinhibitionofcellsafter7days.(B)SingleGAdoseresponse
curve. Points represent the average of six replicates as a percentage growth inhibition of cells after 7 days. (C) Concentrations of VP16 and GA, in combination,
resulting in 50% growth inhibition. The line on the graph connects the points at which the single drug concentrations give 50% inhibition. Combinations that plot
below that line are synergistic (18).
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using the SRB assay, these concentrations were found to be
2.1 mM etoposide (Figure 1A) and 175 nM geldanamycin
(Figure 1B). The concentrations of the two drugs were
decreased and used in a number of different combinations,
the results shown in Figure 1C show that the combinations
tested are synergistic according to the isobolar method (18).
These drugs have little or no effect when used in isolation at
the concentrations tested.
Previously apoptosis for cells treated with doxorubicin
and geldanamycin was established using nuclear frag-
mentation observation (14,15). To demonstrate that the
combination of etoposide (topoisomerase II poison) and
geldanamycin (Hsp90 inhibitor) causes cell death by apoptosis
in HCT116 cells and importantly the timing of this
event; HCT116 cells were treated with 2 mM etoposide,
500 nM geldanamycin or the combination of the two,
over a period of 48 h, the cells were imaged every 15 min.
Figure 2A demonstrates the percentage of cells undergoing
apoptosis, as indicated by the binding of annexin-V.
Figure 2B represents the cumulative total percentage of
cells displaying DNA damage or undergoing apoptosis.
This clearly shows that a greater percentage of cells treated
with the combination of etoposide and geldanamycin are
undergoing apoptosis compared with those treated with the
single drugs. Also in the combination, apoptosis detection
(>5% of cells being Annexin V positive) occurs at  5h
whereas this is only achieved at 20 h for etoposide and 25 h
for geldanamycin.
From these results we conclude that the drug combination
is effective over a range of drug ratios (1 mM etoposide:
42.5 nM geldanamycin to 80 nM etoposide:150 nM geldana-
mycin), that cell death is via apoptosis and more importantly
that this process occurs 15 h earlier in the combination treated
Figure 2. Combinedetoposide(VP16)andgeldanamycin(GA)treatmentofHCT116cellscausescellulardeathbyapoptosis.HCT116cellswereseededatadensity
of 1 · 10
5 cells in 35 mm glass bottom microwell dishes, left to adhere for 96 h. And were treated with 2 mM etoposide (VP16), 500 nM geldanamycin (GA) or a




cells; green ¼ annexin-V; red ¼ propidium iodide. For information, at the 5 h time point the staining of the control cells, no drug treatment was 0.6% with PI and
0.6% with annexinV.
Nucleic Acids Research, 2006, Vol. 34, No. 4 1151cells. In addition, FACs cell cycle analysis data show that
there is virtually no change in the cell cycle distribution
when the different treatment groups are compared, up to
2 h (data not shown).
Topoisomerase II is not degraded in response to
Hsp90 inhibition
Previous studies have shown that upon inhibition of Hsp90,
interacting proteins such as Bcr-Abl are targeted to the
proteasome for degradation (14). To test whether inhibition
of Hsp90 causes degradation of topoisomerase II total cell
lysates,fromHCT116 cellstreatedwith125nMgeldanamycin
over a period of 24 h, were subjected to western blot analysis
using an anti-topoisomerase IIa antibody. Degradation was
not observed until 24 h (Figure 3A).
Figure 3. The effect of geldanmycin on topoisomerase IIa and Chk1 degrada-
tion. HCT116 cells were treated with 1.3 mM geldanamycin over a 24 h period
and total cell extracts taken as indicated above the lanes. Cell lysates were
separated on a 10% SDS–polyacrylamide gel and subsequent western blots
were probed with anti-human topoisomerase IIa (A) anti-human Chk1 (B) and
b-actinantibodies.Theparallelnon-drugtreatedcellsonlycontrolgavearesult
equivalent to the time zero sample.
Figure 4. The effect of Hsp90 inhibition upon topoisomerase II activity. Decatenation of kDNA by a range of volumes (ml) of topoisomerase II extracted from
HCT116WTcells.ExtractswereincubatedwiththeHsp90inhibitorsgeldanamycin(GA)orradicicol(RD)oranequalvolumeofdiluent.Anequivalentvolumeof
the extract was then added to the kDNA assay mixture. (A) A representative image of the effect of Hsp90 inhibition upon topoisomerase II activity. (B) Graphical
representation ofband densitometry analysis.Bars representthe mean of threeindependentexperiments and the error barsrepresent the SE.Treatmentgroupswere
compared using a one-way analysis of variance followed by a comparison of treatment means versus control using the Bonferroni comparison and was noteda s
significant if P < 0.05, * ¼ P < 0.05, ** ¼ P < 0.01.
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Chk1 is a key component of the DNA repair/cell death
decision-making machinery (4). We wished to determine
whether Chk1 plays a role in the synergistic cell killing
observed foran Hsp90 inhibitorand a topoisomerase IIpoison.
HCT116 cells were treated with geldanamycin over a period of
24 h and subjected to western blot analysis using an anti-Chk1
antibody. Figure 3B shows that Chk1 is not degraded in
HCT116 until 8–16 h following treatment with geldanamycin.
This is in agreement with previous studies that showed that
Chk1 was degraded following treatment with the Hsp90
inhibitor 17-AAG (19).
In conclusion we have demonstrated that following treat-
ment with an Hsp90 inhibitor topoisomerase II a degradation
does not occur for at least 5 h after Hsp90 inhibition (this
Figure 5. The effect of drug combinations on comet tail formation. HCT116 cells were treated with etoposide, geldanamycin or a combination of the two over a
periodof24 h and the comettails lengthsof 25cells perdrug treatmentwere determined.(A) Demonstratesthe average comettail lengthvariationovertime. Black
line and diamond ¼ untreated control; blue line and square ¼ etoposide only treatment; green line and triangle ¼ geldanamycin only treatment; red line and
cross ¼ geldanamycin and etoposide combined treatment. (B) Demonstrates the distribution of comet tail lengths over time with the doses as indicated.
Nucleic Acids Research, 2006, Vol. 34, No. 4 1153is also true for topoisomerase II b, data not shown) and that
Chk1 is not degraded for at least 8 h. However, apoptosis
can be observed at 5 h and substantial DNA damage at 1 h
(see below).
Hsp90 inhibition causes an increase in topoisomerase II
catalytic activity
As topoisomerase II is not degraded when Hsp90 is inhibited,
we tested the possibility that topoisomerase II would be
released from the complex, which would result in the
increased topoisomerase II activity. This in turn, could then
be incorporated into lethal cleavable complexes when a topoi-
somerase II poison is present. This would ultimately cause
increased DNA damage and subsequent cell death. An
increase in topoisomerase II activity was initially tested for
in cells treated with geldanamycin, within each experimental
set we observed an increase in topoisomerase II activity over
the non-drug treated control; however, the amount observed
between experiments was highly variable. More reproducible
data were obtained using nuclear extracts from sub-conﬂuent
HCT116 WT cells that were incubated at 37 C with kDNA.
The same nuclear extract was treated with Hsp90 inhibitors,
geldanamycin and radicicol, or an equal volume of diluent
and then incubated with kDNA. The decatenated bands, the
results from three independent experiments, Figure 4A and B,
demonstrates that Hsp90 inhibition results in a signiﬁcant
increase in topoisomerase II catalytic activity. Treatment
groups were compared using a one-way analysis of variance
followed by a comparison of treatment means versus control
using the Bonferroni comparison and was noted as signiﬁcant
if P < 0.05.
Combined etoposide and geldanamycin treatment
causes increased DNA damage in HCT116 cells
As the activity of topoisomerase II is increased in the presence
of an Hsp90 inhibitor we hypothesized that in the presence of
a topoisomerase II poison this would lead to increased DNA
damage. The extent of DNA damage in HCT116 cells, when
treated with the 0.5 mM etoposide and 125 nM geldanamycin
combination, was determined by the comet assay, comet tails
are proportional to the amount of DNA damage (20). After
30 min treatment, comet tails were detected and measured.
The average comet tail length clearly revealed that more DNA
damage occurred when the cells were treated with the
combination of etoposide and geldanamycin (Figure 5A).
After 5 h (300 min) the levels of DNA damage in the cells
treated with the single drugs were almost back to control
levels. However, cells treated with the drug combination
still contained large amounts of damaged DNA, at this time
point. Etoposide and geldanamycin when used alone caused
DNA damage as determined by the formation of comet tails,
but the majority of these only measured between 0 and 50 mm
after subtraction of background levels in untreated samples.
However, the combination of etoposide and geldanamycin
caused an increase in the number of larger comet tail lengths,
the majority of which were between 151 and 200 mm
(Figure 5B). These results show that there is a dramatic
increase in DNA damage observable at 1 h with the combina-
tion drug treatment and that this DNA damage remains
constant possibly at a far greater level than DNA repair
mechanisms can sustain. As a comment on the comet assay
data, the early observable DNA damage is likely to be caused
as a result of the presence of cleavable complexes; the later
observable damage is probably a combination of cleavable
complexes and apoptotic induced DNA degradation, with
the relative contributions changing over time.
Combined etoposide and geldanamycin treatment
causes increased topoisomerase II–DNA cleavable
complex formation in HCT116 cells, ICE assay
If our hypothesis is correct we would predict that the increase
in DNA damage, at 1 h, is mediated via topoisomerase II–drug
stabilized cleavable complexes. To conﬁrm that the increase in
DNA damage was topoisomerase II mediated HCT116 WT
cells were treated with 2 mM etoposide, 500 nM geldanamycin
or the combination of the two drugs for 1 h. The cells were
then lysed and cell lysates were applied onto pre-formed CsCl
step gradients and subjected to ultra-centrifugation for 24 h.
Fractions were collected and applied onto nitrocellulose
membranes and the presence of the DNA enzyme complex
was tested for using an antibody against topoisomerase IIa.
The DNA content of each fraction was estimated by agarose
gel electrophoresis. There were no topoisomerase IIa–DNA
complexes in the control or the geldanamycin treated cells. As
expected, etoposide when used alone produced some topoi-
somerase IIa–DNA complexes; however, the amount of
complexes dramatically increased when the two drugs were
used in combination (Figure 6).
Figure 6. Effect of VP16 and GA on topoIIa–DNA complexes. Cells were
treated with 2 mM VP16, 500 nM GA and the combination of the two for 1 h.
Cells were collected and lysed with 1% sarkosyl, loaded onto pre-formed CsCl
stepgradientsandcentrifugedat30000r.p.m.for24h.Fractionswerecollected
and applied onto nitrocellulose membranes, which were immunoblotted with
anti-human topoisomerase IIa antibodies. Lanes 13–18 not shown.
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Hsp90 inhibitors enhance the efﬁcacy of topoisomerase II
poisons (Figure 1) (5,14,15). Effective killing and topoi-
somerase II associated DNA damage is achieved after 1 h
after treatment.
Many previous models for the sensitization of cell to drugs
when used in combination with Hsp90 inhibition have focused
on the degradation of Hsp90 client proteins. Hypoxia-
inducible factor 1a (HIF-1a) an oxygen-regulated transcrip-
tion factor which plays a critical role in the tumour cell
response to hypoxia is associated with Hsp90, and degradation
of HIF-1a by the proteasomal pathway is induced by geldana-
mycin (21). Inhibition of Hsp90 by geldanamycin has also
been demonstrated to cause the degradation of ErbB-2
via proteolytic fragmentation leading to the formation of intra-
cellular vesicles (22). Chk1 immunoprecipitates with Hsp90
and the role of Chk1 degradation following Hsp90 inhibition
in sensitization of cells to topoisomerase I poisons has been
the subject of a number of recent publications (23–25).
Proposing that, at least in part, this effect is mediated through
removal of the DNA damage induced cell cycle blockade.
However, it is important to note that it is degraded 8–16 h
following treatment with 17-AAG or geldanamycin
(Figure 3B) (19).
Topoisomerase II poisons induce apoptotic cell death by
causing double-strand breaks in the DNA. The enzyme is
required to be present in order to generate the drug stabilized
cleavable complex therefore its degradation would be counter
productive if the enhanced cell killing effect is mediated
via topoisomerase II. Figure 3A clearly shows that topoi-
somerase II is not degraded. On the contrary drug induced
dissociation of the interaction between topoisomerase II and
Hsp90 by geldanamycin or radicicol leads to an increase in
topoisomerase II activity (Figure 4), this effect would be
advantageous to the stabilization of the topoisomerase II
cleavable complex. Increased topoisomerase mediated
cell killing should equate with a concomitant increase in topoi-
somerase II-speciﬁc DNA damage as shown in Figures 4
and 6.
Topoisomerase II induced DNA damage is normally sensed
by ataxia-telangiectasia mutated (ATM) or Rad3-related
A
B C
Figure 7. Potential model for the mechanism of action. (A) Under ‘normal’ conditions, in the nuclei, topoisomerase II performs its function of maintaining DNA
topology.(B) Upontreatmentwitha topoisomeraseII poison,the topoisomerase IIis lockedontotheDNA holdingitin anopenconformation(cleavablecomplex).
However, under these conditions a proportion of the topoisomerase II forms an inactive complex with Hsp90. (C) Hsp90 drugs disrupt the direct Hsp90–
topoisomerase II interaction thus leading to an increase in unbound topoisomerase II which, if then treated with a topoisomerase II poison, leads to the formation
of more cleavable complexes. This would ultimately result in an increase in DNA and subsequently cell death.
Nucleic Acids Research, 2006, Vol. 34, No. 4 1155kinase (ATR), which signal a cascade of events leading to cell
cycle arrest mediated via Chk1, allowing DNA repair or apop-
totic death [for a review see (4)] When considering the role of
Hsp90 inhibition as a blockade removal processes, i.e. the
degradation of Chk1, the timing of events should be con-
sidered. Firstly Chk1 is only degraded after 8 h, at the earliest,
whereas there is a massive increase in DNA damage at 1 h in
the combination treatment (Figure 5) and the ICE assay
(Figure 6), which is also performed at 1 h conﬁrms that the
majority of this is topoismerase II mediated. Our previous
clonogenic assays studies were performed with 1 h exposure
to the drugs which was then washed out also support an early
pre 8 h event (5).
Therefore from the data outlined above we propose the
following model to explain the synergistic co-operation of
a topoisomerase II poison with an Hsp90 inhibitor. This
proposal requires that following Hsp90 inhibition an active
form of topoisomerase II be released. This was raised as a pos-
sibility, in our previous paper (5) along with an alternate
where the effect could be due to independent activities of
the drugs as described recently for topoisomerase I, where
Hsp90 inhibitor-induced degradation of Chk1 sensitized
tumour cells to chemotherapy due to loss of DNA damage
check point control. The key to our model is that the lethal
topoisomerase II mediated damage is observed at 1 h as
opposed to a model based on Chk1 degradation where
DNA damage could not occur until post 8 h, because the
Chk1 block would still be present.
Our study is not alone in proposing that Hsp90 client
proteins may be released, in an active form, after protection.
This has been demonstrated previously for the dissociation of
the Hsp90-Hsf-1 heterocomplexes, which results in the forma-
tion of active Hsf-1 trimers that are then able to regulate heat
shock gene transcription (26).
Figure 7 outlines our model. Under normal conditions
within the nuclei topoisomerase II performs its function of
maintaining DNA topology (Figure 7A). Upon treatment
with a topoisomerase II poison, the topoisomerase II is locked
onto the DNA holding it in an open conformation (cleavable
complex). The Hsp90 protects a population of the topoi-
somerase II by association (Figure 7B). The Hsp90 inhibitor
disruptstheHsp90-topoisomeraseIIinteractionthus leading to
an increase in unbound topoisomerase II and activation, which
if in the presence of a topoisomerase II poison, would lead to
the formation of more cleavable complexes (Figure 7C). This
would ultimately result in an increase in DNA damage and
subsequently cell death. A caveat to this is that a certain
amount of topoisomerase II may already be complexed with
Hsp90 in the non-drug treated cell.
In conclusion our work establishes that Hsp90 and topoi-
somerase II form a complex and that upon treatment with
an Hsp90 inhibitor and a topoisomerase IIpoison, asynergistic
inhibition effect is observed. Inhibition of Hsp90 causes
an increase in topoisomerase II activity in vitro, which is
further evidence that disruption of Hsp90 interactions can
lead to the activation of client proteins. This may not be a
complete answer and there may indeed be a contribu-
tion from cell cycle blockade removal. It is, however, an
interesting alternative model, which, following further invest-
igation, could lead to a beneﬁcial less toxic chemotherapeutic
regime.
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